

Prevalence and Outcome of Thrombocytopenia in Systemic Lupus Erythematosus – Single Centre Cohort Analysis

Tatiana Costa Pires¹, Raquel Caparrós-Ruiz², Pedro Gaspar³, David Isenberg⁴

1. Tatiana Costa Pires - Serviço de Medicina 1, Hospital de Santo André, Centro Hospitalar de Leiria, Leiria, Portugal

2. Raquel Caparrós-Ruiz - UGC de Reumatologia, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga, Málaga, Spain

3. Pedro Gaspar - Serviço de Medicina 2, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal

4. David Isenberg, Centre for Rheumatology, Division of Medicine, University College London

Abstract:

Objectives: To characterize the frequency of thrombocytopenia in patients with SLE and determine its time of onset during the course of the disease, severity and impact on mortality.

Methods: This was a single centre cohort analysis of 707 patients with SLE followed for up to 40 years. We reviewed the patients' clinical notes identifying the presence of thrombocytopenia, its time of onset and ascertained other clinical and serological features of the disease. Thrombocytopenia was classified as mild ($100-149 \times 10^9/L$), moderate ($31-99 \times 10^9/L$) or severe ($\leq 30 \times 10^9/L$ platelets). It was also classified as asymptomatic, with minor bleeding or with major bleeding.

Results: 22.9% of patients (n=162) had thrombocytopenia prior to or during the course of SLE. Twenty three patients (14.2%) had isolated ITP before the diagnosis of SLE. Median follow-up time was 19 years (IQR=13). Most patients (N=67, 41.4%) had mild thrombocytopenia. More than half the patients (n=98, 60.5%) developed asymptomatic thrombocytopenia and only 6 patients (3.7%) had major bleeding events in the context of thrombocytopenia. The development of severe thrombocytopenia anytime during the course of SLE was associated with an increased risk of death (HR=3.57, p=0.025). There was an increased risk of death for male patients (HR=3.41, p=0.036) who develop thrombocytopenia and for those who presented with concomitant haemolytic anaemia (HR=3.07, p=0.027).

Conclusion: The presence of severe thrombocytopenia (platelets $\leq 30 \times 10^9$) in patients with SLE is associated with an increased risk of death, regardless of bleeding events. Male patients with SLE and thrombocytopenia had an increased mortality risk, as have those who develop concomitant thrombocytopenia and haemolytic anaemia.

Introduction:

Thrombocytopenia is a common hematological feature of SLE, affecting 10–40% of patients with this disorder¹⁻³. It can predate other features of SLE, presenting as isolated ITP⁴. Severe thrombocytopenia, however, is relatively rare⁵. The presence of thrombocytopenia has been associated with other severe manifestations of SLE, such as neuropsychiatric and/or kidney involvement and haemolytic anemia⁶⁻⁸. Thrombocytopenia also appears to have an impact on the prognosis of SLE, including mortality^{3,9-11}, although contradictory results have been reported^{6,12}.

The aim of this study was to characterize the frequency of thrombocytopenia in SLE in a large cohort followed for very long periods of time (up to 40 years), to determine its time of onset during the course of the disease, as well as its severity. We also aimed to characterize the impact of thrombocytopenia on morbidity – mainly in bleeding – and mortality.

Methods:

All available clinical and lupus clinic notes from a cohort of 707 patients with SLE, followed since January 1979 were reviewed. Patients with less than 5 years follow-up were excluded. We identified patients that developed thrombocytopenia (defined as platelet count $<150 \times 10^9/L$) anytime during the course of the disease, including those that presented with isolated ITP before the diagnosis of SLE. Thrombocytopenia was classified as mild ($100-149 \times 10^9/L$ platelets), moderate ($31-99 \times 10^9/L$ platelets) or severe ($\leq 30 \times 10^9/L$ platelets). It was also classified as asymptomatic (no relation to any bleeding event), with minor bleeding (thrombocytopenia in relation with non-life threatening bleeding events such as epistaxis or gum bleeding) or with major bleeding (thrombocytopenia in relation to life threatening bleeding events such as major gastro-intestinal haemorrhage or haemorrhagic stroke). Other clinical features of the disease were noted: age at diagnosis, time elapsed since the diagnosis of SLE to the appearance of thrombocytopenia (or between the diagnosis of ITP and the diagnosis of SLE), the presence of mucocutaneous manifestations of SLE, such as rash, photosensitivity, alopecia or oral ulcers; joint, kidney or CNS involvement, the presence of serositis or secondary Sjogren's syndrome, as well as the presence of other hematological features, such as hemolytic anemia, leucopenia or lymphopenia. Serological features of the disease were also noted, namely positivity for dsDNA antibodies, anti-Sm, anti-Ro, anti-La and anti-RNP antibodies, the presence of low complement C3, Rheumatoid factor, Lupus anticoagulant and anticardiolipin antibodies.

Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) software (version 22.0). Univariable Cox proportional hazard models were conducted to screen for predictors of mortality. Multivariable Cox proportional hazard models were then applied to the predictors that showed $p < .10$. A case-control study was also performed comparing the patients who developed thrombocytopenia with the remainder of the cohort. Chi-square tests were used for categorical variables and T-tests were used for the continuous variables.

Significance was considered for 0.05. Marginally significant results ($p < .10$) were considered for retaining variables in multivariate final models contributing for a more comprehensive data adjustment.

Results:

A total of 162 patients (22.9%) were identified as having developed thrombocytopenia prior to or sometime during the course of SLE, from a cohort of 707. The mean age at diagnosis of SLE was 28.47 +/- 13.31 years, ranging from 7 to 77 years old; 148 patients (91.4%) were female and 14 (8.6%) were male. Caucasian was the most prevalent ethnic origin ($n=94$; 58.0%). Twenty three patients (14.2%) had isolated ITP before the diagnosis of SLE. Sample characteristics are compiled in Table 1.

The median time from diagnosis of SLE to development of thrombocytopenia was 8 years (IQR=14). Most patients ($N=67$, 41.4%) had mild thrombocytopenia, 41 (25.3%) moderate and 42 (25.9%) severe thrombocytopenia. More than half the patients ($N=98$, 60.5%) developed asymptomatic thrombocytopenia, while 35 (21.6%) presented with minor bleeding but only 6 patients (3.7%) had major bleeding events in the context of thrombocytopenia.

Univariable Survival Analysis with Cox regression models was performed to screen for significant predictors of mortality. These were found to be older age at diagnosis (HR=1.06; $p < .001$) and severe thrombocytopenia (HR=3.59; $p=.019$). Thrombocytopenia diagnosed after lupus (as opposed to previous ITP) was not associated risk of death (HR=0.45; $p=.088$). When considering the survival rates after the development of thrombocytopenia, higher death risk was found for older patients at time of diagnosis (HR=1.02; $p=0.047$), males (HR=3.77; $p=0.020$), patients with concomitant haemolytic anaemia (HR=2.73; $p=0.037$) and concomitant serositis (HR=2.33; $p=0.040$). No significant association was found with increased DNA binding (HR=2.58; $p=0.085$). There was no association found between bleeding events (of any severity) and mortality.

When a Multivariable Survival analysis was performed, higher age at diagnosis (HR=1.07; $p < .001$) and the development of severe thrombocytopenia (HR=3.57; $p=0.025$) were confirmed as associated with an increased risk of death. Regarding survival time after the development of thrombocytopenia, our results confirmed increased mortality risk for older patients at diagnosis of SLE (HR=1.03; $p=0.015$), males (HR=3.41; $p=0.036$) and those with concomitant haemolytic anaemia (HR=3.07; $p=0.027$). These results are summarized in table 2.

A case control analysis was conducted, using the patients in the lupus cohort that did not develop thrombocytopenia ($N=545$). Mean age in the control group was 29.15 +/- 13.33 years, ranging from 7 to 75 years old; 500 patients (91.4%) were female and 45 (8.3%) were male. Caucasian was the most prevalent ethnic group ($n=314$; 57.6%). A comparison of disease characteristics is shown in Table 3.

Sex prevalence distribution was similar in both groups, with more than 90% of females ($p=0.893$). Significant differences were found for ethnic group ($p<0.001$) with higher prevalence of South Asian in the disease group (11.7% vs 2.8%) and higher prevalence of Caucasians in the control group (57.6% vs 47.7%). No significant differences were found with respect to age at diagnosis ($p=0.483$).

The comparison of predictors between groups showed that haemolytic anaemia ($p<0.001$), leucopenia ($p=0.002$), and kidney involvement ($p<0.001$) were more prevalent in the thrombocytopenia group. Positive Rheumatoid Factor ($p=0.019$), low complement C3 ($p=0.022$) and non-erosive joint involvement ($p<0.001$) were more prevalent in the control group. These characteristics are summarized in table 4.

A Logistic Regression was applied, with thrombocytopenia as outcome (results summarized in table 5). Patients of South Asian ethnicity have an increased risk for the development of thrombocytopenia (OR=5.54) when compared with Caucasian patients ($p=0.004$). Haemolytic Anaemia (OR=18.09; $p<0.001$), leucopenia (OR=2.63, $p=0.024$) and positive Lupus Anticoagulant (OR=4.11; $p<0.001$) are also associated with an increased risk of developing thrombocytopenia.

Discussion:

Twenty-three percent of patients in our cohort of 707 SLE patients followed for periods of up to 40 years developed thrombocytopenia sometime during the course of their disease. This is in line with previously published prevalence data¹⁻³. Of these 162 patients, 23 (14.2%) had thrombocytopenia as a first manifestation of SLE (initially diagnosed as ITP).

Also in accordance with previously published results^{13,14}, Most patients (N=67, 41.4%) in our cohort developed only mild thrombocytopenia (100×10^9 - 149×10^9 /L platelets). Twenty-five percent of patients (N=41) had moderate thrombocytopenia (31×10^9 - 99×10^9 /L platelets) and 25.9% (N=42) had severe thrombocytopenia ($\leq 30 \times 10^9$ platelets/L).

More than half the patients in this cohort (N=98, 60.5%) developed asymptomatic thrombocytopenia. Only 6 patients (3.7%) had major bleeding events in the context of thrombocytopenia and only one patient died as a direct complication of thrombocytopenia. These results are also in line with previous reports¹⁴⁻¹⁶. Although thrombocytopenia is a common feature of SLE, symptomatic thrombocytopenia is rare.

The presence of severe thrombocytopenia (platelets $\leq 30 \times 10^9$) in patients with SLE is associated with an increased risk of death, in this cohort. This risk is independent of bleeding events. Several authors^{5-7,9-11} have tried to establish the prognostic value of assessing the severity of thrombocytopenia in SLE, with varied results. *Jung et al*¹⁶ found a similar association between severe thrombocytopenia and mortality in a cohort of 230 patients. Our greater numbers and longer follow-up time permit us to confirm these results.

Male patients with SLE who develop thrombocytopenia (any degree) appear to have an increased mortality risk in this cohort. The simultaneous appearance of other severe

haematological abnormalities, namely haemolytic anaemia carries an increased mortality risk in patients with lupus thrombocytopenia.

Predictors for the development of thrombocytopenia, in our cohort, include, as in other cohorts^{5,13,14}, the presence of haemolytic anaemia, leucopenia and positive lupus anticoagulant. We found no association with neuropsychiatric involvement as reported by *Sultan et al*¹³. Besides these commonly described predictors, we also found an increased risk for the development of thrombocytopenia in patients of South Asian ethnicity (5.5 fold increase in risk in this population).

Although a common manifestation of SLE, thrombocytopenia may be a marker of severe disease as it is associated with other organ involvement, notably with lupus nephritis and other haematological complications, such as haemolytic anaemia. These patients require close monitoring, especially those who develop severe thrombocytopenia, as this finding is, by itself linked with higher mortality risk.

References:

1. Fayyaz A, Igoe A, Kurien BT, *et al*. Haematological manifestations of lupus. *Lupus Sci Med*. 2015;2:e000078.
2. Keeling DM, Isenberg DA. Haematological manifestations of systemic lupus erythematosus. *Blood Rev*. 1993;7:199–207.
3. Nossent JC, Swaak AJG. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. *Q J Med* 1991;80:605–12.
4. Rabinowitz Y, Dameshk W. Systemic lupus erythematosus after idiopathic thrombocytopenic purpura. A review. *Ann Intern Med* 1960;52:1–28.
5. Ziakas PD, Giannouli S, Zintzaras E, Tzioufas AG, Voulgarelis M. Lupus thrombocytopenia: clinical implications and prognostic significance. *Ann. Rheum. Dis*. 2005;64:1366e1369.
6. Miller MH, Urowitz MB, Gladman DD. The significance of thrombocytopenia in systemic lupus erythematosus. *Arthritis Rheum*. 1983;26:1181–1186.
7. Zhao H, Li S, Yang R. Thrombocytopenia in patients with systemic lupus erythematosus: significant in the clinical implication and prognosis. *Platelets*. 2010;21:380–385.
8. Feinglass EJ, Arnett FC, Dorsch CA, *et al*. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. *Medicine (Baltimore)*. 1976;55:323–339.
9. Fernandez M, Alarcon GS, Apte M, *et al*. Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor. *Arthritis Rheum*. 2007;56:614–621.
10. Patel N, Mody GM. Acute Presentation of thrombocytopenia in systemic lupus erythematosus is associated with a high mortality in South Africa. *Lupus*. 2014;23:204-212.
11. Reveille JD, Bartolucci A, Alarcón GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. *Arthritis Rheum* 1990;33:37–48.

12. Swaak AJ, Nossent JC, Bronsveld W, *et al.* Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. *Ann Rheum Dis* 1989;48:447–54.
13. Sultan SM, Begum S, Isenberg DA. Prevalence, patterns of disease, and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. *Rheumatology* 2003;42:230-234.
14. Ktona E, Barbullushi M, Backa T, Idrizi A, Shpata V, Roshi E. Evaluation of thrombocytopenia in systemic lupus erythematosus and correlation with different organs damages. *Mater Sociomed.* 2014;26:122–4.
15. Li J, Pan Z, Liu H *et al.* Retrospective analysis of the risk of hemorrhage associated with moderate and severe thrombocytopenia of 173 patients with systemic lupus erythematosus. *Medicine.* 2018;97:27:e11356
16. Jung JH, Soh MS, Ahn YH *et al.* Thrombocytopenia in Systemic Lupus Erythematosus. Clinical Manifestations, treatment and prognosis in 230 patients. *Medicine.* 2016;95(6):e2818.

Table 1. Characteristics of SLE with thrombocytopenia

Variable	n (%)
Sex	
Female	148 (91.4%)
Male	14 (8.6%)
Ethnic origin	
Caucasian	94 (58.0%)
Black	18 (11.1%)
Chinese	6 (3.7%)
South Asian	19 (11.7%)
Other Asian Background	10 (6.2%)
Other/Mixed Ethnic Origin	15 (9.2%)
Thrombocytopenia	
Previous ITP	23 (14.2%)
After SLE diagnosis	139 (85.5%)
Degree of Thrombocytopenia	
Mild	67 (41.4%)
Moderate	41 (25.3%)
Severe	42 (25.9%)
Unknown	12 (7.4%)
Bleeding	
Asymptomatic	98 (60.5%)
Minor bleeding	35 (21.6%)
Major bleeding	6 (3.7%)
Unknown	23 (14.2%)

Table 2. Multivariable Survival analysis

	<i>Lupus → death/last contact</i>		<i>Patients With Thrombocytopenia → death/last contact</i>	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Age at diagnosis	1.07 (1.03;1.10)	<0.001	1.03 (1.01; 1.06)	0.015
Sex				
Female	-	-	1	1
Male	-	-	3.41 (1.08; 10.73)	0.036
Thrombocytopenia				
Previous ITP	1	1	-	-
After SLE diagnosis	1.23 (0.34;4.51)	0.751	-	-
Degree of thrombocytopenia				
Mild	1	1		
Moderate	0.98 (0.27;3.54)	0.970		
Severe	3.57 (1.18;10.81)	0.025		
Unknown	1.88 (0.49;7.15)	0.355		
Haemolytic anaemia				
No	-	-	1	1
Yes	-	-	3.07 (1.614; 4.54)	0.027
Serositis				
No	-	-	1	1
Yes	-	-	2.05 (0.91; 4.63)	0.084
DNA				
No	-	-	2.45 (0.76; 7.91)	0.136
Yes	-	-		

Table 3. Sample characteristics comparison (thrombocytopenia vs control group)

<i>Variable</i>	<i>Thrombocytopenia n (%) (n=163)</i>	<i>Control n (%) (n=545)</i>	<i>p-value</i>
Sex			0.893
Female	149 (91.4%)	500 (91.7%)	
Male	14 (8.6%)	45 (8.3%)	
Ethnic origin			<0.001
Caucasian	94 (47.7%)	314 (57.6%)	
Black	18 (1.0%)	42 (7.7%)	
Chinese	6 (3.7%)	29 (5.3%)	
South Asian	19 (11.7%)	15 (2.8%)	
Other Asian	10 (6.2%)	48 (8.8%)	
Others	15 (9.2%)	97 (17.8%)	

NS = not significant

Table 4. Predictors comparison (thrombocytopenia vs control group)

<i>Predictor</i>	<i>Thrombocytopenia</i>		<i>Control</i>		<i>p-value</i>
	n	%	n	%	
Haemolytic anaemia	25	15.4%	15	2.8%	<0.001
Leucopenia	61	37.7%	137	25.2%	0.002
Lymphopenia	123	75.9%	403	74.1%	0.636
Rash	106	65.4%	357	65.6%	0.964
Photosens	60	37.0%	217	40.0%	0.503
Alopecia	43	26.5%	127	23.3%	0.397
Oral ulcers	40	24.7%	145	26.8%	0.601
Serositis	61	37.7%	203	37.2%	0.925
Kidney	72	44.4%	158	29.0%	<0.001
CNS	42	25.9%	112	20.6%	0.152
SJOGREN	12	7.4%	54	10.0%	0.318
RF	26	16.0%	131	24.9%	0.019
SM	26	16.1%	96	17.7%	0.652
RNP	51	31.5%	160	29.4%	0.604
RO	61	37.7%	217	39.9%	0.609
LA	17	10.5%	87	16.0%	0.083
DNA	114	70.4%	335	62.4%	0.063
C3	91	56.5%	251	46.2%	0.022
Joint					<0.001
No joint involvement	20	12.9%	55	10.1%	
Non-erosive	135	87.1%	490	89.9%	

Table 5. Logistic regression with thrombocytopenia as outcome

<i>Predictor</i>	<i>OR</i>	<i>p-value</i>	<i>95% CI</i>
Ethnic origin			
Caucasian	1	1	
Other Asian	3.06	0.106	(0.79; 11.91)
Black	2.04	0.235	(0.63; 6.60)
Chinese	4.49	0.086	(0.81; 24.92)
South Asian	5.54	0.004	(1.75; 17.54)
Others	0.26	0.071	(0.06; 1.12)
Haemolytic Anaemia			
No	1	1	
Yes	18.09	<0.001	(6.74; 48.58)
Leucopenia			
No	1	1	
Yes	2.63	0.024	(1.13; 6.11)
Alopecia			
No	1	1	
Yes	5.62	0.002	(1.86; 16.98)
LA			
No	1	1	
Yes	4.11	<0.001	(1.92; 8.81)